TherapeuticsMD (TXMD) Liabilities and Shareholders Equity (2010 - 2026)

TherapeuticsMD's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $37.6 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.71% year-over-year to $37.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152.4 million (down 2.76% YoY) and the FY2025 annual result came in at $37.7 million, down 3.0% from the prior year.
• Liabilities and Shareholders Equity was $37.6 million for Q1 2026 at TherapeuticsMD, roughly flat from $37.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $146.2 million in Q2 2022 and bottomed at $37.6 million in Q1 2026.
• A 5-year average of $62.5 million and a median of $42.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 63.28% — and 2026, when it slipped 1.71%.
• TherapeuticsMD's Liabilities and Shareholders Equity stood at $90.5 million in 2022, then sank by 52.12% to $43.3 million in 2023, then slipped by 10.36% to $38.8 million in 2024, then fell by 3.0% to $37.7 million in 2025, then retreated by 0.2% to $37.6 million in 2026.
• Business Quant data shows TXMD's Liabilities and Shareholders Equity at $37.6 million in Q1 2026, $37.7 million in Q4 2025, and $38.7 million in Q3 2025.